Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors

Urologia Internationalis

Volumn 87, Issue 2, 2011, Pages 134-137

  Jovanovic, M ^a   Soldatovic, I ^b   Janjic, A ^a   Vuksanovic, A ^a   Dzamic, Z ^a   Acimovic, M ^a   Hadzi Djokic, J ^a  

^a Clinical Center of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cytology; Nuclear matrix protein 22; Upper urothelial tumor

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CYTOPATHOLOGY; HUMAN; HUMAN CELL; NEPHROLITHIASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; UPPER TRACT UROTHELIAL CARCINOMA; URINALYSIS; URINARY CATHETER;

ADULT; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; RISK; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; UROLOGY; UROTHELIUM;

EID: 80052743193     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000330246     Document Type: Article

References (17)

1. Tinyl M, Marberger M: Urinary marker for detecting bladder cancer. Eur Urol 2003; 1: 64-70. (Pubitemid 40411074)
2. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology results of a comprehensive literature review and metaanalyses. Urology 2003; 61: 109-116.
3. Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A: Comparison of the monoclonal UBC-Elisa test and the NMP22 Elisa test for the detection of urothelial cell carcinoma of the bladder. Urology 2000; 50: 223-226. (Pubitemid 30069920)
4. Siemens DR, Morales A, Johnston B, Emerson L: A comparative analysis of rapid urine tests for the diagnosis of upper urinary tract malignancy. Can J Urol 2003; 10: 1754-1758.
5. Oosterlinck W, Solsona E, van der Meijden APM, Sylvester R, Bohle A, Rintala E, Lobel B: EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol 2004; 46: 147-154. (Pubitemid 38902728)
6. Munoz J, Ellison LM: Upper tract urothelial neoplasm: Incidence and survival the last 2 decades. J Urol 2000; 164: 1523.
7. van Rhijn BWG, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005; 47: 736-748. (Pubitemid 40745338)
8. Chahal R, Darshane A, Browing AJ, Sundaram SK: Evaluation of the clinical value of urinary NMP 22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 2001; 40: 415-421. (Pubitemid 34032819)
9. Ponsky L, Harma S, Pandrangi L, Kedia S, Nelson D, Agrawal A, Zippe C: Screening and monitoring for bladder cancer: Refining the use of NMP22. J Urol 2001; 166: 75-78. (Pubitemid 32565346)
10. Tritcheler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D: Validation of the diagnostic value of NMP22 BladderChek Test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007; 51: 403-408. (Pubitemid 44937800)
11. Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulou M, et al: Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2000; 55: 871-875. (Pubitemid 30330790)
12. Bian Y, Ehya H, Bagley DH: Cytologic diagnosis of upper urinary tract neoplasms by ureteroscopic sampling. Acta Cytol 1995; 39: 733-740.
13. Nabi G, Greene DR, O'Donnell M: How important is urinary cytology in the diagnosis of urological malignancies? Eur Urol 2003; 43: 632-636. (Pubitemid 36648603)
14. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, et al: Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006; 176: 919-926. (Pubitemid 44160707)
15. Menedez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, et al: Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Anticancer Res 2000; 20: 1169-1172. (Pubitemid 30240695)
16. Konety BR, Getzenberg RH: Urine based marker of urological malignancy. J Urol 2001; 165: 600-611. (Pubitemid 32060487)
17. Grossman H, Messing E, Soloway M, et al: Detection of bladder cancer using a point-of care proteomic assay. JAMA 2005; 293: 810-816. (Pubitemid 40250364)